1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Kim JJ, Park JK and Moon SW: Usefulness of
positron emission tomography-computed tomography in pre-operative
evaluation of intra-thoracic esophageal cancer. Thorac Cancer.
6:687–694. 2015. View Article : Google Scholar : PubMed/NCBI
|
3
|
Miyata H, Yamasaki M, Kurokawa Y,
Takiguchi S, Nakajima K, Fujiwara Y, Konishi K, Mori M and Doki Y:
Survival factors in patients with recurrence after curative
resection of esophageal squamous cell carcinomas. Ann Surg Oncol.
18:3353–3361. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Akutsu Y and Matsubara H: Chemotherapy and
surgery for T4 esophageal cancer in Japan. Surg Today.
45:1360–1365. 2015. View Article : Google Scholar : PubMed/NCBI
|
5
|
Martens-Uzunova ES, Olvedy M and Jenster
G: Beyond microRNA-novel RNAs derived from small non-coding RNA and
their implication in cancer. Cancer Lett. 340:201–211. 2013.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Lu C, Shan Z, Li C and Yang L: miR-129
regulates cisplatin-resistance in human gastric cancer cells by
targeting P-gp. Biomed Pharmacother. 86:450–456. 2017. View Article : Google Scholar : PubMed/NCBI
|
7
|
Mutlu M, Raza U, Saatci O, Eyupoglu E,
Yurdusev E and Sahin O: miR-200c: A versatile watchdog in cancer
progression, EMT, and drug resistance. J Mol Med (Berl).
94:629–644. 2016. View Article : Google Scholar : PubMed/NCBI
|
8
|
Lang B, Shang C and Meng L: Targeted
silencing of S100A8 gene by miR-24 increase chemotherapy
sensitivity of endometrial carcinoma cells to paclitaxel. Med Sci
Monit. 22:1953–1958. 2016. View Article : Google Scholar : PubMed/NCBI
|
9
|
Sun C, Yao X, Jiang Q and Sun X: miR-106b
targets DAB2 to promote hepatocellular carcinoma cell proliferation
and metastasis. Oncol Lett. 16:3063–3069. 2018.PubMed/NCBI
|
10
|
Bu W, Wang Y and Min X: microRNA-106b
promotes the proliferation, migration and invasion of
retinoblastoma cells by inhibiting the expression of ZBTB4 protein.
Exp Ther Med. 16:4537–4545. 2018.PubMed/NCBI
|
11
|
Jiao D, Yan Y, Shui S, Wu G, Ren J, Wang Y
and Han X: miR-106b regulates the 5-fluorouracil resistance by
targeting Zbtb7a in cholangiocarcinoma. Oncotarget. 8:52913–52922.
2017. View Article : Google Scholar : PubMed/NCBI
|
12
|
Dai F, Liu T, Zheng S, Liu Q, Yang C, Zhou
J, Chen Y, Shehidin I and Lu X: miR-106b promotes migration and
invasion through enhancing EMT via downregulation of Smad 7 in
Kazakh's esophageal squamous cell carcinoma. Tumor Biol.
37:14959–14604. 2016. View Article : Google Scholar
|
13
|
Yu S, Qin X, Chen T, Zhou L, Xu X and Feng
J: microRNA-106b-5p regulates cisplatin chemosensitivity by
targeting polycystic kidney disease-2 in non-small-cell lung
cancer. Anticancer Drugs. 28:852–860. 2017. View Article : Google Scholar : PubMed/NCBI
|
14
|
Yao GD, Zhang YF, Chen P and Ren XB:
MicroRNA-544 promotes colorectal cancer progression by targeting
forkhead box O1. Oncol Lett. 15:991–997. 2018.PubMed/NCBI
|
15
|
Long XH, Shi Y, Ye P, Guo J, Zhou Q and
Tang YT: MicroRNA-99a suppresses breast cancer progression by
targeting FGFR3. Front Oncol. 9:14732019. View Article : Google Scholar : PubMed/NCBI
|
16
|
Ni SJ, Weng WW, Xu MD, Wang QF, Tan C, Sun
H, Wang L, Huang D, Du X and Sheng WQ: miR-106b-5p inhibits the
invasion and metastasis of colorectal cancer by targeting CTSA.
Onco Targets Ther. 11:3835–3845. 2018. View Article : Google Scholar : PubMed/NCBI
|
17
|
Zhou YT, Tian WH, Zhang M, Ren TH, Sun GR,
Jiang RR, Han RL, Kang XT and Yan FB: Transcriptom analysis
revealed regulation of dexamethasone induced microRNAs in chicken
thymus. J Cell Biochem. 120:6570–6579. 2019. View Article : Google Scholar : PubMed/NCBI
|
18
|
Wu XB, Cao W, Wang X, Zhang JJ, Lv ZJ, Qin
X, Wu YD and Chen WT: TGM3, a candidate tumor suppressor gene,
contributes to human head and neck cancer. Mol Cancer. 12:1512013.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Feng Y, Ji D, Huang Y, Ji B, Zhang Y, Li
J, Peng W, Zhang C, Zhang D, Sun Y and Xu Z: TGM3 functions as a
tumor suppressor by repressing epithelial-to-mesenchymal transition
and the PI3K/AKT signaling pathway in colorectal cancer. Oncol Rep.
43:864–876. 2020.PubMed/NCBI
|
20
|
Livak KJ and Schimittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Wu J, Wang L, Du X, Sun Q, Wang Y, Li M,
Zang W, Liu K and Zhao G: α-solanine enhances the chemosensitivity
of esophageal cancer cells by inducing microRNA-138 expression.
Oncol Rep. 39:1163–1172. 2018.PubMed/NCBI
|
22
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:e050052015. View Article : Google Scholar : PubMed/NCBI
|
23
|
Steven AC and Steinert PM: Protein
composition of cornified cell envelopes of epidermal keratinocytes.
J Cell Sci. 107:693–700. 1994. View Article : Google Scholar : PubMed/NCBI
|
24
|
Luo A, Kong J, Hu G, Liew CC, Xiong M,
Wang X, Ji J, Wang T, Zhi H, Wu M and Liu Z: Discovery of
CA2+-relevant and differentiation-associated genes downregulated in
esophageal squamous cell carcinoma using cDNA microarray.
Oncotarget. 23:1291–1299. 2004.PubMed/NCBI
|
25
|
Wu X, Cao W, Wang X, Zhang J, Lv Z, Qin X,
Wu Y and Chen W: TGM3, a candidate tumor suppressor gene,
contributes to human head and neck cancer. Mol Cancer. 12:1512013.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Wu X, Wang R, Jiao J, Li S, Yu J, Yin Z,
Zhou L and Gong Z: Transglutaminase 3 contributes to malignant
transformation of oral leukoplakia to cancer. Int J Biochem Cell
Biol. 104:34–42. 2018. View Article : Google Scholar : PubMed/NCBI
|
27
|
He G, Zhao Z, Fu W, Sun X, Xu Z and Sun K:
Study on the loss of heterozygosity and expression of
transglutaminase 3 gene in laryngeal carcinoma. Zhonghua Yi Xue Yi
Chuan Xue Za Zhi. 19:120–123. 2002.(In Chinese). PubMed/NCBI
|
28
|
Negishi A, Masuda M, Ono M, Honda K,
Shitashige M, Satow R, Sakuma T, Kuwabara H, Nakanishi Y, Kanai K,
et al: Quantitative proteomics using formalin-fixed
paraffin-embedded tissues of oral squamous cell carcinoma. Cancer
Sci. 100:1605–1611. 2009. View Article : Google Scholar : PubMed/NCBI
|
29
|
Stacey SN, Sulem P, Gudbjartsson DF,
Jonasdottir A, Thorleifsson G, Gudjonsson SA, Masson G, Gudmundsson
J, Sigurgeirsson B, Benediktsdottir KR, et al: Germline sequence
variants in TGM3 and RGS22 confer risk of basal cell carcinoma. Hum
Mol Genet. 23:3045–3053. 2014. View Article : Google Scholar : PubMed/NCBI
|
30
|
Liu W, Yu ZC, Cao WF, Ding F and Liu ZH:
Functional studies of a novel oncogene TGM3 in human esophageal
squamous cell carcinoma. World J Gastroenterol. 12:3929–3932. 2006.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Li W, Zhang Z, Zhao W and Han N:
Transglutaminase 3 protein modulated human esophageal cancer cell
growth by targeting the NF-κB signaling pathway. Oncol Rep.
36:1723–1730. 2016. View Article : Google Scholar : PubMed/NCBI
|
32
|
Uemura N, Nakanishi Y, Kato H, Saito S,
Nagino M, Hirohashi S and Kondo T: Transglutaminase 3 as a
prognostic biomarker in esophageal cancer revealed by proteomics.
Int J Cancer. 124:2106–2115. 2009. View Article : Google Scholar : PubMed/NCBI
|
33
|
Tian H, Hou L, Xiong YM, Huang JX, She YJ,
Bi XB and Song XR: miR-218 suppresses tumor growth and enhances the
chemosensitivity of esophageal squamous cell carcinoma to
cisplatin. Oncol Rep. 33:981–989. 2015. View Article : Google Scholar : PubMed/NCBI
|
34
|
Zheng TL, Li DP, He ZF and Zhao S: miR-145
sensitizes esophageal squamous cell carcinoma to cisplatin through
directly inhibiting PI3K/AKT signaling pathway. Cancer Cell Int.
19:2502019. View Article : Google Scholar : PubMed/NCBI
|
35
|
Lin WC, Chen LH, Hsieh YC, Yang PW, Lai
LC, Chuang EY, Lee JM and Tsai HM: miR-338-5p inhibits cell
proliferation, colony formation, migration and cisplatinresistance
in esophageal squamous cancer cells by targeting FERMT2.
Carcinogenesis. 40:883–892. 2019. View Article : Google Scholar : PubMed/NCBI
|
36
|
Zhao Y, Ma K, Yang S, Zhang X, Wang F,
Zhang X, Liu H and Fan Q: MicroRNA-125a-5p enhances the sensitivity
of esophageal squamous cell carcinoma cells to cisplatin by
suppressing the activation of the STAT3 signaling pathway. Int J
Oncol. 53:644–658. 2018.PubMed/NCBI
|
37
|
Fang Y, Zhou W, Rong Y, Kuang T, Xu X, Wu
W, Wang D and Lou W: Exosomal miRNA-106b from cancer-associated
fibroblast promotes gemcitabine resistance in pancreatic cancer.
Exp Cell Res. 383:1115432019. View Article : Google Scholar : PubMed/NCBI
|